Chenxia Duan, Yi Zhu, Zhuoliang Zhang, Tiantian Wu, Mengwei Shen, Jinfu Xu, Wenxin Gao, Jianhua Pan, Lei Wei, Huibin Su, Chenghuan Shi
Cancer-induced bone pain (CIBP) is one of the most common and feared symptoms in patients with advanced tumors. The X-C motif chemokine ligand 12 (CXCL12) and the CXCR4 receptor have been associated with glial cell activation in bone cancer pain. Moreover, mitogen-activated protein kinases (MAPKs), as downstream CXCL12/CXCR4 signals, and c-Jun, as activator protein AP-1 components, contribute to the development of various types of pain. However, the specific CIBP mechanisms remain unknown. Esketamine is a non-selective N-methyl-D-aspartic acid receptor (NMDA) inhibitor commonly used as an analgesic in the clinic, but its analgesic mechanism in bone cancer pain remains unclear...
February 28, 2024: Molecular Pain